Phase 2 Gastric Junction Adenocarcinoma Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 2
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma
Gastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital88 enrolled1 locationNCT07569068
Recruiting
Phase 2
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
Peritoneal Metastases From Gastric CancerGastric Cancer Stage IVGastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital74 enrolled1 locationNCT07556640
Recruiting
Phase 2
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
Gastric AdenocarcinomaEsophagogastric Junction Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences70 enrolled1 locationNCT06761846
Recruiting
Phase 2
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Gastric CancerEsophagogastric Junction Adenocarcinoma
Zekuan Xu30 enrolled1 locationNCT06461910
Recruiting
Phase 2Phase 3
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
Gastric CancerImmunotherapyNeoadjuvant Therapies+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology80 enrolled1 locationNCT06826079
Recruiting
Phase 2
Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
Esophagogastric Junction Adenocarcinoma
Sun Yat-sen University37 enrolled1 locationNCT05170503
Recruiting
Phase 2
Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study
Esophagogastric Junction Adenocarcinoma
Ruijin Hospital26 enrolled1 locationNCT06482788